ArticleJournal of veterinary internal medicine2026
Effect of trilostane treatment on proteinuria secondary to spontaneous hypercortisolism in dogs.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProteinuria is reported in 68%-71% of dogs with spontaneous hypercortisolism (HC). The long-term effect of trilostane on HC-associated proteinuria remains poorly documented. HYPOTHESIS/
objectivesTo evaluate the efficacy of trilostane on proteinuria in dogs with HC and identify potential clinical, anamnestic, and analytical differences between responders and nonresponders.
methodsRetrospective longitudinal cohort study including dogs with proteinuric HC treated exclusively with trilostane. Clinical history and laboratory data at diagnosis (T0) were retrieved. When available, urine protein-to-creatinine ratio (UPC), disease clinical score (DCS), blood pressure (BP), and daily trilostane dosage (TD) were recorded at 30, 90, 180, and 365 days (T30, T90, T180, and T365) after treatment initiation. Dogs achieving a ≥ 50% UPC reduction or a final UPC < 0.5 were defined as "responders."
resultsOne hundred sixty dogs met inclusion criteria: 89% had pituitary-dependent HC and 10% adrenal-dependent HC. At diagnosis, 64% were proteinuric. A significant UPC reduction over time occurred (P = .0005; F(4,153.9) = 5.26), with statistically significant decreases at T90 (P = .020; difference, 1.093; 95% CI, 0.115-2.071), T180 (P = .031; difference, 1.122; 95% CI, 0.064-2.181), and T365 (P = .002; difference, 1.599; 95% CI, 0.436-2.761) compared to baseline. At the last follow-up, 76 dogs were evaluable; 48% were responders and had lower median DCS, BP, and TD (P = .029, P = .025, and P = .048, respectively) than nonresponders. CONCLUSIONS AND CLINICAL IMPORTANCE: Trilostane induces a significant and sustained reduction in proteinuria in some dogs with spontaneous HC, evident from 3 months of treatment. Responders exhibit better control of hypertension and clinical signs despite lower TD. Nonresponders account for 52% of proteinuric dogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.